georgie18
2月前
ARTL...$5.83...🥳...Coming off the $4 range bottom on News...
georgie18
Re: georgie18 post# 169
Tuesday, March 31, 2026 9:28:41 AM
Post#
174
of 174
ARTL...$10.26...🥳...Starting up again...
georgie18
Member Level
Re: georgie18 post# 166
Friday, March 27, 2026 12:57:27 PM
Post#
169
of 173
ARTL...$16.27...🥳...Hit $19.90....
georgie18
Member Level
Re: georgie18 post# 718442
Friday, March 27, 2026 11:58:53 AM
Post#
718451
of 718461
ARTL...$14.13...🥳...Close to a 10 Bagga from my earlier $1.69 ...Alert...
georgie18
Member Level
Re: georgie18 post# 164
Friday, March 27, 2026 11:45:45 AM
Post#
165
of 165
ARTL...$12.66...🥳...Off my $3.26 Alert...
georgie18
Member Level
Re: georgie18 post# 718400
Friday, March 27, 2026 10:01:15 AM
Post#
718412
of 718441
ARTL...$10.80...🥳...Hit $12 plus...
georgie18
Member Level
Re: georgie18 post# 162
Friday, March 27, 2026 8:56:57 AM
Post#
163
of 163
ARTL...$8.39...🥳...Off my $3.26 Alert...
georgie18
Member Level
Re: None
Thursday, March 26, 2026 9:02:26 AM
Post#
718284
of 718399
ARTL...$3.26...🥳...Zero Shares to Borrow...Last alert $1.69 to $9.00 range...
georgie18
2月前
ARTL...$10.26...🥳...Starting up again...
georgie18
Member Level
Re: georgie18 post# 166
Friday, March 27, 2026 12:57:27 PM
Post#
169
of 173
ARTL...$16.27...🥳...Hit $19.90....
georgie18
Member Level
Re: georgie18 post# 718442
Friday, March 27, 2026 11:58:53 AM
Post#
718451
of 718461
ARTL...$14.13...🥳...Close to a 10 Bagga from my earlier $1.69 ...Alert...
georgie18
Member Level
Re: georgie18 post# 164
Friday, March 27, 2026 11:45:45 AM
Post#
165
of 165
ARTL...$12.66...🥳...Off my $3.26 Alert...
georgie18
Member Level
Re: georgie18 post# 718400
Friday, March 27, 2026 10:01:15 AM
Post#
718412
of 718441
ARTL...$10.80...🥳...Hit $12 plus...
georgie18
Member Level
Re: georgie18 post# 162
Friday, March 27, 2026 8:56:57 AM
Post#
163
of 163
ARTL...$8.39...🥳...Off my $3.26 Alert...
georgie18
Member Level
Re: None
Thursday, March 26, 2026 9:02:26 AM
Post#
718284
of 718399
ARTL...$3.26...🥳...Zero Shares to Borrow...Last alert $1.69 to $9.00 range...
STLHD7
2月前
Do your own ARTL DD but sharing info on the months out dilution & current short squeeze setup...
11mil funding – The 3.18mil shares are dead weight and can’t be sold on market or used by shorts to cover…typically takes 15–30 days just to file the paperwork + another 30–60 days for the SEC to declare it "effective."
"Rhyming" Markers: The Short Squeeze Setup
Extreme Borrow Fees: ARTL’s short borrow fee recently spiked to 616.17%. This "rhymes" with the 100%+ fees seen during the height of the GME squeeze, where the cost to maintain a short position becomes unsustainable, forcing shorts to "buy to cover".
Massive Volume Multiplier: On March 27, 2021, GME traded multiples of its float. Similarly, on March 27, 2026, ARTL traded over 81 million shares—more than 115 times its post-reverse-split float of ~708,000 shares. This level of "churn" is a hallmark of a violent short squeeze.
The "Pivot Bottom" Bounce: Technical analysts noted a "pivot bottom" on March 26, 2026, which triggered a 230% price jump. This rapid, vertical price action mimics the "gap and trap" moves that initiated the GME and AMC rallies.
High Short Volume Ratio: Intraday data shows a short volume ratio of 72.93%, indicating that the majority of trading activity is still dominated by short sellers betting against the rally, creating a "coiled spring" effect
georgie18
2月前
ARTL...$16.27...🥳...Hit $19.90....
georgie18
Member Level
Re: georgie18 post# 718442
Friday, March 27, 2026 11:58:53 AM
Post#
718451
of 718461
ARTL...$14.13...🥳...Close to a 10 Bagga from my earlier $1.69 ...Alert...
georgie18
Member Level
Re: georgie18 post# 164
Friday, March 27, 2026 11:45:45 AM
Post#
165
of 165
ARTL...$12.66...🥳...Off my $3.26 Alert...
georgie18
Member Level
Re: georgie18 post# 718400
Friday, March 27, 2026 10:01:15 AM
Post#
718412
of 718441
ARTL...$10.80...🥳...Hit $12 plus...
georgie18
Member Level
Re: georgie18 post# 162
Friday, March 27, 2026 8:56:57 AM
Post#
163
of 163
ARTL...$8.39...🥳...Off my $3.26 Alert...
georgie18
Member Level
Re: None
Thursday, March 26, 2026 9:02:26 AM
Post#
718284
of 718399
ARTL...$3.26...🥳...Zero Shares to Borrow...Last alert $1.69 to $9.00 range...
georgie18
2月前
ARTL...$14.13...🥳...Close to a 10 Bagga from my earlier $1.69 ...Alert...
georgie18
Member Level
Re: georgie18 post# 164
Friday, March 27, 2026 11:45:45 AM
Post#
165
of 165
ARTL...$12.66...🥳...Off my $3.26 Alert...
georgie18
Member Level
Re: georgie18 post# 718400
Friday, March 27, 2026 10:01:15 AM
Post#
718412
of 718441
ARTL...$10.80...🥳...Hit $12 plus...
georgie18
Member Level
Re: georgie18 post# 162
Friday, March 27, 2026 8:56:57 AM
Post#
163
of 163
ARTL...$8.39...🥳...Off my $3.26 Alert...
georgie18
Member Level
Re: None
Thursday, March 26, 2026 9:02:26 AM
Post#
718284
of 718399
ARTL...$3.26...🥳...Zero Shares to Borrow...Last alert $1.69 to $9.00 range...
georgie18
2月前
ARTL...$12.66...🥳...Off my $3.26 Alert...
georgie18
Member Level
Re: georgie18 post# 718400
Friday, March 27, 2026 10:01:15 AM
Post#
718412
of 718441
ARTL...$10.80...🥳...Hit $12 plus...
georgie18
Member Level
Re: georgie18 post# 162
Friday, March 27, 2026 8:56:57 AM
Post#
163
of 163
ARTL...$8.39...🥳...Off my $3.26 Alert...
georgie18
Member Level
Re: None
Thursday, March 26, 2026 9:02:26 AM
Post#
718284
of 718399
ARTL...$3.26...🥳...Zero Shares to Borrow...Last alert $1.69 to $9.00 range...
georgie18
3月前
ARTL...$9.70...🥳...Beauty runner off my $1.69 Alert...
georgie18
Member Level
Re: georgie18 post# 717748
Friday, March 20, 2026 9:37:26 AM
Post#
717749
of 717750
ARTL...$8.95...🥳
georgie18
Member Level
Re: georgie18 post# 156
Friday, March 20, 2026 9:35:25 AM
Post#
158
of 158
ARTL...$8.26...🥳...Off my $1.69 Alert...
georgie18
Member Level
Re: georgie18 post# 717550
Wednesday, March 18, 2026 8:14:46 AM
Post#
717554
of 717747
ARTL...$7.36...🥳...Beauty move on News...
georgie18
Member Level
Re: georgie18 post# 154
Wednesday, March 18, 2026 8:01:40 AM
Post#
155
of 155
ARTL...$6.30...🥳... https://finviz.com/news/338218/artelo-announces-third-party-fully-funded-clinical-study-agreement-to-evaluate-art2713-in-glaucoma-patients
georgie18
Member Level
Re: georgie18 post# 707845
Thursday, December 04, 2025 4:05:16 PM
Post#
708003
of 717550
ARTL...$2.02...🥳...
georgie18
Member Level
Re: tw0122 post# 149
Wednesday, December 03, 2025 2:27:45 PM
Post#
151
of 153
ARTL...$1.69...🥳... Notice of Effectiveness hit right into today's news...This prospectus relates to the offer and resale, from time to time, by the selling securityholders named in this prospectus (the “Selling Securityholders”) of up to an aggregate of 899,972 shares of common stock, par value $0.001 per share (“Common Stock”), of Artelo Biosciences, Inc., consisting of (i) 215,292 shares of Common Stock issuable upon the conversion of convertible notes (the “Notes”), (ii) 246,498 shares of Common Stock issuable upon the exercise of warrants at an exercise price of $6.24 per share (the “$6.24 Warrants”), and (iii) 438,182 shares of Common Stock issuable upon the exercise of warrants at an exercise price of $3.40 per share (the “$3.40 Warrants”). The $6.24 Warrants and the $3.40 Warrants are collectively referred to herein as the “Warrants.” The shares of Common Stock issuable upon the conversion of the Notes and the Warrants are collectively referred to herein as the “Shares.”
The $6.24 Warrants were issued to the Selling Securityholders on October 28, 2025, upon the automatic conversion of a portion of the May 2025 Notes (as defined below) issued to the Selling Securityholders in a private placement that closed on May 1, 2025 (the “May 2025 Private Placement”), pursuant to a subscription agreement that we entered into with the Selling Securityholders, effective May 1, 2025 (the “May 2025 Subscription Agreement”). The Notes and the $3.40 Warrants were issued and sold to the Selling Securityholders in a private placement that closed on October 28, 2025 (the “October 2025 Private Placement”), pursuant to a subscription agreement among us and such selling stockholders effective October 28, 2025 (the “October 2025 Subscription Agreement,” and together with the May 2025 Subscription Agreement, the “Subscription Agreements”). We are filing the registration statement of which this prospectus is a part pursuant to the Subscription Agreements on behalf of the Selling Securityholders.
We will not receive any proceeds from the sale of the Shares by the Selling Securityholders. We will, however, receive the net proceeds of any Warrants exercised for cash. Our registration of the Shares covered by this prospectus does not mean that the Selling Securityholders will offer or sell any of the Shares.
We will bear all costs, expenses and fees in connection with the registration of the Shares. The Selling Securityholders will bear all commissions and discounts, if any, attributable to their sales of the Shares. The Selling Securityholders and any of their permitted transferees may offer and sell the shares covered by this prospectus in a number of different ways and at varying prices. The Securities and Exchange Commission may take a position that each of the Selling Securityholders is an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended (the “Securities Act”). Additional information on the Selling Securityholders, and the times and manner in which they may offer and sell shares of our Common Stock under this prospectus, is provided under “Selling Securityholders” and “Plan of Distribution” in this prospectus.
Our Common Stock is traded on the Nasdaq Capital Market under the symbol “ARTL.” The last reported sales price of our shares of Common Stock on November 14, 2025 was $1.85 per share.
georgie18
3月前
ARTL...$8.95...🥳
georgie18
Member Level
Re: georgie18 post# 156
Friday, March 20, 2026 9:35:25 AM
Post#
158
of 158
ARTL...$8.26...🥳...Off my $1.69 Alert...
georgie18
Member Level
Re: georgie18 post# 717550
Wednesday, March 18, 2026 8:14:46 AM
Post#
717554
of 717747
ARTL...$7.36...🥳...Beauty move on News...
georgie18
Member Level
Re: georgie18 post# 154
Wednesday, March 18, 2026 8:01:40 AM
Post#
155
of 155
ARTL...$6.30...🥳... https://finviz.com/news/338218/artelo-announces-third-party-fully-funded-clinical-study-agreement-to-evaluate-art2713-in-glaucoma-patients
georgie18
Member Level
Re: georgie18 post# 707845
Thursday, December 04, 2025 4:05:16 PM
Post#
708003
of 717550
ARTL...$2.02...🥳...
georgie18
Member Level
Re: tw0122 post# 149
Wednesday, December 03, 2025 2:27:45 PM
Post#
151
of 153
ARTL...$1.69...🥳... Notice of Effectiveness hit right into today's news...This prospectus relates to the offer and resale, from time to time, by the selling securityholders named in this prospectus (the “Selling Securityholders”) of up to an aggregate of 899,972 shares of common stock, par value $0.001 per share (“Common Stock”), of Artelo Biosciences, Inc., consisting of (i) 215,292 shares of Common Stock issuable upon the conversion of convertible notes (the “Notes”), (ii) 246,498 shares of Common Stock issuable upon the exercise of warrants at an exercise price of $6.24 per share (the “$6.24 Warrants”), and (iii) 438,182 shares of Common Stock issuable upon the exercise of warrants at an exercise price of $3.40 per share (the “$3.40 Warrants”). The $6.24 Warrants and the $3.40 Warrants are collectively referred to herein as the “Warrants.” The shares of Common Stock issuable upon the conversion of the Notes and the Warrants are collectively referred to herein as the “Shares.”
The $6.24 Warrants were issued to the Selling Securityholders on October 28, 2025, upon the automatic conversion of a portion of the May 2025 Notes (as defined below) issued to the Selling Securityholders in a private placement that closed on May 1, 2025 (the “May 2025 Private Placement”), pursuant to a subscription agreement that we entered into with the Selling Securityholders, effective May 1, 2025 (the “May 2025 Subscription Agreement”). The Notes and the $3.40 Warrants were issued and sold to the Selling Securityholders in a private placement that closed on October 28, 2025 (the “October 2025 Private Placement”), pursuant to a subscription agreement among us and such selling stockholders effective October 28, 2025 (the “October 2025 Subscription Agreement,” and together with the May 2025 Subscription Agreement, the “Subscription Agreements”). We are filing the registration statement of which this prospectus is a part pursuant to the Subscription Agreements on behalf of the Selling Securityholders.
We will not receive any proceeds from the sale of the Shares by the Selling Securityholders. We will, however, receive the net proceeds of any Warrants exercised for cash. Our registration of the Shares covered by this prospectus does not mean that the Selling Securityholders will offer or sell any of the Shares.
We will bear all costs, expenses and fees in connection with the registration of the Shares. The Selling Securityholders will bear all commissions and discounts, if any, attributable to their sales of the Shares. The Selling Securityholders and any of their permitted transferees may offer and sell the shares covered by this prospectus in a number of different ways and at varying prices. The Securities and Exchange Commission may take a position that each of the Selling Securityholders is an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended (the “Securities Act”). Additional information on the Selling Securityholders, and the times and manner in which they may offer and sell shares of our Common Stock under this prospectus, is provided under “Selling Securityholders” and “Plan of Distribution” in this prospectus.
Our Common Stock is traded on the Nasdaq Capital Market under the symbol “ARTL.” The last reported sales price of our shares of Common Stock on November 14, 2025 was $1.85 per share.
georgie18
3月前
ARTL...$8.26...🥳...Off my $1.69 Alert...
georgie18
Member Level
Re: georgie18 post# 717550
Wednesday, March 18, 2026 8:14:46 AM
Post#
717554
of 717747
ARTL...$7.36...🥳...Beauty move on News...
georgie18
Member Level
Re: georgie18 post# 154
Wednesday, March 18, 2026 8:01:40 AM
Post#
155
of 155
ARTL...$6.30...🥳... https://finviz.com/news/338218/artelo-announces-third-party-fully-funded-clinical-study-agreement-to-evaluate-art2713-in-glaucoma-patients
georgie18
Member Level
Re: georgie18 post# 707845
Thursday, December 04, 2025 4:05:16 PM
Post#
708003
of 717550
ARTL...$2.02...🥳...
georgie18
Member Level
Re: tw0122 post# 149
Wednesday, December 03, 2025 2:27:45 PM
Post#
151
of 153
ARTL...$1.69...🥳... Notice of Effectiveness hit right into today's news...This prospectus relates to the offer and resale, from time to time, by the selling securityholders named in this prospectus (the “Selling Securityholders”) of up to an aggregate of 899,972 shares of common stock, par value $0.001 per share (“Common Stock”), of Artelo Biosciences, Inc., consisting of (i) 215,292 shares of Common Stock issuable upon the conversion of convertible notes (the “Notes”), (ii) 246,498 shares of Common Stock issuable upon the exercise of warrants at an exercise price of $6.24 per share (the “$6.24 Warrants”), and (iii) 438,182 shares of Common Stock issuable upon the exercise of warrants at an exercise price of $3.40 per share (the “$3.40 Warrants”). The $6.24 Warrants and the $3.40 Warrants are collectively referred to herein as the “Warrants.” The shares of Common Stock issuable upon the conversion of the Notes and the Warrants are collectively referred to herein as the “Shares.”
The $6.24 Warrants were issued to the Selling Securityholders on October 28, 2025, upon the automatic conversion of a portion of the May 2025 Notes (as defined below) issued to the Selling Securityholders in a private placement that closed on May 1, 2025 (the “May 2025 Private Placement”), pursuant to a subscription agreement that we entered into with the Selling Securityholders, effective May 1, 2025 (the “May 2025 Subscription Agreement”). The Notes and the $3.40 Warrants were issued and sold to the Selling Securityholders in a private placement that closed on October 28, 2025 (the “October 2025 Private Placement”), pursuant to a subscription agreement among us and such selling stockholders effective October 28, 2025 (the “October 2025 Subscription Agreement,” and together with the May 2025 Subscription Agreement, the “Subscription Agreements”). We are filing the registration statement of which this prospectus is a part pursuant to the Subscription Agreements on behalf of the Selling Securityholders.
We will not receive any proceeds from the sale of the Shares by the Selling Securityholders. We will, however, receive the net proceeds of any Warrants exercised for cash. Our registration of the Shares covered by this prospectus does not mean that the Selling Securityholders will offer or sell any of the Shares.
We will bear all costs, expenses and fees in connection with the registration of the Shares. The Selling Securityholders will bear all commissions and discounts, if any, attributable to their sales of the Shares. The Selling Securityholders and any of their permitted transferees may offer and sell the shares covered by this prospectus in a number of different ways and at varying prices. The Securities and Exchange Commission may take a position that each of the Selling Securityholders is an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended (the “Securities Act”). Additional information on the Selling Securityholders, and the times and manner in which they may offer and sell shares of our Common Stock under this prospectus, is provided under “Selling Securityholders” and “Plan of Distribution” in this prospectus.
Our Common Stock is traded on the Nasdaq Capital Market under the symbol “ARTL.” The last reported sales price of our shares of Common Stock on November 14, 2025 was $1.85 per share.
iHub News
3月前
Artelo Biosciences moves into glaucoma research with fully funded clinical studyMarch 18, 2026 11:00 AM
IH Market News
Artelo Biosciences (NASDAQ:ARTL) is expanding its development pipeline into ophthalmology with a new clinical study evaluating its drug candidate ART27.13 for the treatment of glaucoma. The San Diego–based clinical-stage biotech company said the investigator-sponsored trial will be fully funded through support from Glaucoma UK and the Health and Social Care (HSC) Research & Development Division, with the first patient expected to enroll in the second quarter of 2026.The move represents a strategic diversification of Artelo’s pipeline while avoiding the need for additional shareholder-funded equity financing.
Targeting a rapidly growing global market
The global glaucoma treatment market continues to expand as the number of patients rises. The sector was valued at about $9.46 billion in 2025 and is projected to reach roughly $16.3 billion by 2033, growing at an estimated annual rate of just over 7%.Glaucoma affects millions worldwide. Around 145.9 million people were living with the disease in 2021, with the number expected to increase to about 166 million by 2026. In the United States alone, approximately 4.2 million adults had glaucoma in 2022, including roughly 1.5 million experiencing vision impairment. That number is projected to rise to 6.3 million by 2050.While the patient population continues to grow, treatment innovation has struggled to keep pace, creating an opportunity for new therapeutic approaches.
ART27.13 aims to address unmet needs
Many current glaucoma therapies focus on lowering intraocular pressure (IOP), which is a key risk factor for disease progression. However, a significant number of patients continue to experience vision loss despite treatment.Artelo’s ART27.13 is designed to target a different biological pathway. The compound is a peripherally selective synthetic cannabinoid receptor agonist that primarily activates CB2 receptors. Preclinical studies suggest the drug may help regulate intraocular pressure through effects on aqueous humor dynamics and ocular blood flow, while also offering anti-inflammatory and neuroprotective benefits.By focusing on peripheral CB2 receptor activity, ART27.13 aims to avoid the central nervous system side effects that historically limited the clinical development of cannabinoid-based treatments for eye diseases.
Investigator-sponsored trial structure
The study will be led by Professor Augusto Azuara-Blanco at Queen’s University Belfast and conducted by the Northern Ireland Clinical Trials Unit. The pilot study, titled “A Pilot, Randomized, Cross-Over Study to Determine the Effects of an Oral, Peripherally Selective, Synthetic Cannabinoid ART27.13 on Intraocular Pressure,” will evaluate the drug’s impact on intraocular pressure in glaucoma patients.Because the trial is investigator-sponsored, the funding is provided externally while Artelo retains strategic oversight and rights to the study data. This model can help biotechnology companies advance clinical programs while preserving capital.The crossover design of the trial will allow each participant to serve as their own control, improving statistical power while potentially reducing the number of patients required and shortening development timelines.“This collaboration broadens ART27.13’s therapeutic profile beyond cancer-related anorexia while preserving our internal focus on the lead indication,” said Greg D. Gorgas, President and CEO of Artelo Biosciences.
Multiple programs in development
ART27.13 is also being developed for cancer-related anorexia. Interim results from the Phase 2 CAReS study have shown improvements in body weight, lean body mass and physical activity among patients receiving the drug, along with a favorable safety profile.In addition, Artelo recently received a Notice of Allowance from the European Patent Office covering the intended commercial formulation of ART27.13, extending potential patent protection in Europe through December 2041.Beyond ART27.13, the company is developing therapies that target lipid-signaling pathways for conditions including cancer, pain, dermatological disorders and neurological diseases.
Upcoming milestones
Key milestones for the company include the start of patient enrollment in the glaucoma pilot trial in the second quarter of 2026, continued progress in the Phase 2 CAReS trial for cancer-related anorexia, and advancement of its broader pipeline programs.Artelo Biosciences is a clinical-stage biotechnology company headquartered in San Diego that focuses on developing therapies designed to modulate the endocannabinoid system for a range of serious medical conditions.Artelo Biosciences stock price
Original: Artelo Biosciences moves into glaucoma research with fully funded clinical study
georgie18
3月前
ARTL...$7.36...🥳...Beauty move on News...
georgie18
Member Level
Re: georgie18 post# 154
Wednesday, March 18, 2026 8:01:40 AM
Post#
155
of 155
ARTL...$6.30...🥳... https://finviz.com/news/338218/artelo-announces-third-party-fully-funded-clinical-study-agreement-to-evaluate-art2713-in-glaucoma-patients
georgie18
Member Level
Re: georgie18 post# 707845
Thursday, December 04, 2025 4:05:16 PM
Post#
708003
of 717550
ARTL...$2.02...🥳...
georgie18
Member Level
Re: tw0122 post# 149
Wednesday, December 03, 2025 2:27:45 PM
Post#
151
of 153
ARTL...$1.69...🥳... Notice of Effectiveness hit right into today's news...This prospectus relates to the offer and resale, from time to time, by the selling securityholders named in this prospectus (the “Selling Securityholders”) of up to an aggregate of 899,972 shares of common stock, par value $0.001 per share (“Common Stock”), of Artelo Biosciences, Inc., consisting of (i) 215,292 shares of Common Stock issuable upon the conversion of convertible notes (the “Notes”), (ii) 246,498 shares of Common Stock issuable upon the exercise of warrants at an exercise price of $6.24 per share (the “$6.24 Warrants”), and (iii) 438,182 shares of Common Stock issuable upon the exercise of warrants at an exercise price of $3.40 per share (the “$3.40 Warrants”). The $6.24 Warrants and the $3.40 Warrants are collectively referred to herein as the “Warrants.” The shares of Common Stock issuable upon the conversion of the Notes and the Warrants are collectively referred to herein as the “Shares.”
The $6.24 Warrants were issued to the Selling Securityholders on October 28, 2025, upon the automatic conversion of a portion of the May 2025 Notes (as defined below) issued to the Selling Securityholders in a private placement that closed on May 1, 2025 (the “May 2025 Private Placement”), pursuant to a subscription agreement that we entered into with the Selling Securityholders, effective May 1, 2025 (the “May 2025 Subscription Agreement”). The Notes and the $3.40 Warrants were issued and sold to the Selling Securityholders in a private placement that closed on October 28, 2025 (the “October 2025 Private Placement”), pursuant to a subscription agreement among us and such selling stockholders effective October 28, 2025 (the “October 2025 Subscription Agreement,” and together with the May 2025 Subscription Agreement, the “Subscription Agreements”). We are filing the registration statement of which this prospectus is a part pursuant to the Subscription Agreements on behalf of the Selling Securityholders.
We will not receive any proceeds from the sale of the Shares by the Selling Securityholders. We will, however, receive the net proceeds of any Warrants exercised for cash. Our registration of the Shares covered by this prospectus does not mean that the Selling Securityholders will offer or sell any of the Shares.
We will bear all costs, expenses and fees in connection with the registration of the Shares. The Selling Securityholders will bear all commissions and discounts, if any, attributable to their sales of the Shares. The Selling Securityholders and any of their permitted transferees may offer and sell the shares covered by this prospectus in a number of different ways and at varying prices. The Securities and Exchange Commission may take a position that each of the Selling Securityholders is an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended (the “Securities Act”). Additional information on the Selling Securityholders, and the times and manner in which they may offer and sell shares of our Common Stock under this prospectus, is provided under “Selling Securityholders” and “Plan of Distribution” in this prospectus.
Our Common Stock is traded on the Nasdaq Capital Market under the symbol “ARTL.” The last reported sales price of our shares of Common Stock on November 14, 2025 was $1.85 per share.
georgie18
3月前
ARTL...$6.30...🥳... https://finviz.com/news/338218/artelo-announces-third-party-fully-funded-clinical-study-agreement-to-evaluate-art2713-in-glaucoma-patients
georgie18
Member Level
Re: georgie18 post# 707845
Thursday, December 04, 2025 4:05:16 PM
Post#
708003
of 717550
ARTL...$2.02...🥳...
georgie18
Member Level
Re: tw0122 post# 149
Wednesday, December 03, 2025 2:27:45 PM
Post#
151
of 153
ARTL...$1.69...🥳... Notice of Effectiveness hit right into today's news...This prospectus relates to the offer and resale, from time to time, by the selling securityholders named in this prospectus (the “Selling Securityholders”) of up to an aggregate of 899,972 shares of common stock, par value $0.001 per share (“Common Stock”), of Artelo Biosciences, Inc., consisting of (i) 215,292 shares of Common Stock issuable upon the conversion of convertible notes (the “Notes”), (ii) 246,498 shares of Common Stock issuable upon the exercise of warrants at an exercise price of $6.24 per share (the “$6.24 Warrants”), and (iii) 438,182 shares of Common Stock issuable upon the exercise of warrants at an exercise price of $3.40 per share (the “$3.40 Warrants”). The $6.24 Warrants and the $3.40 Warrants are collectively referred to herein as the “Warrants.” The shares of Common Stock issuable upon the conversion of the Notes and the Warrants are collectively referred to herein as the “Shares.”
The $6.24 Warrants were issued to the Selling Securityholders on October 28, 2025, upon the automatic conversion of a portion of the May 2025 Notes (as defined below) issued to the Selling Securityholders in a private placement that closed on May 1, 2025 (the “May 2025 Private Placement”), pursuant to a subscription agreement that we entered into with the Selling Securityholders, effective May 1, 2025 (the “May 2025 Subscription Agreement”). The Notes and the $3.40 Warrants were issued and sold to the Selling Securityholders in a private placement that closed on October 28, 2025 (the “October 2025 Private Placement”), pursuant to a subscription agreement among us and such selling stockholders effective October 28, 2025 (the “October 2025 Subscription Agreement,” and together with the May 2025 Subscription Agreement, the “Subscription Agreements”). We are filing the registration statement of which this prospectus is a part pursuant to the Subscription Agreements on behalf of the Selling Securityholders.
We will not receive any proceeds from the sale of the Shares by the Selling Securityholders. We will, however, receive the net proceeds of any Warrants exercised for cash. Our registration of the Shares covered by this prospectus does not mean that the Selling Securityholders will offer or sell any of the Shares.
We will bear all costs, expenses and fees in connection with the registration of the Shares. The Selling Securityholders will bear all commissions and discounts, if any, attributable to their sales of the Shares. The Selling Securityholders and any of their permitted transferees may offer and sell the shares covered by this prospectus in a number of different ways and at varying prices. The Securities and Exchange Commission may take a position that each of the Selling Securityholders is an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended (the “Securities Act”). Additional information on the Selling Securityholders, and the times and manner in which they may offer and sell shares of our Common Stock under this prospectus, is provided under “Selling Securityholders” and “Plan of Distribution” in this prospectus.
Our Common Stock is traded on the Nasdaq Capital Market under the symbol “ARTL.” The last reported sales price of our shares of Common Stock on November 14, 2025 was $1.85 per share.
georgie18
6月前
ARTL...$2.02...🥳...
georgie18
Member Level
Re: tw0122 post# 149
Wednesday, December 03, 2025 2:27:45 PM
Post#
151
of 153
ARTL...$1.69...🥳... Notice of Effectiveness hit right into today's news...This prospectus relates to the offer and resale, from time to time, by the selling securityholders named in this prospectus (the “Selling Securityholders”) of up to an aggregate of 899,972 shares of common stock, par value $0.001 per share (“Common Stock”), of Artelo Biosciences, Inc., consisting of (i) 215,292 shares of Common Stock issuable upon the conversion of convertible notes (the “Notes”), (ii) 246,498 shares of Common Stock issuable upon the exercise of warrants at an exercise price of $6.24 per share (the “$6.24 Warrants”), and (iii) 438,182 shares of Common Stock issuable upon the exercise of warrants at an exercise price of $3.40 per share (the “$3.40 Warrants”). The $6.24 Warrants and the $3.40 Warrants are collectively referred to herein as the “Warrants.” The shares of Common Stock issuable upon the conversion of the Notes and the Warrants are collectively referred to herein as the “Shares.”
The $6.24 Warrants were issued to the Selling Securityholders on October 28, 2025, upon the automatic conversion of a portion of the May 2025 Notes (as defined below) issued to the Selling Securityholders in a private placement that closed on May 1, 2025 (the “May 2025 Private Placement”), pursuant to a subscription agreement that we entered into with the Selling Securityholders, effective May 1, 2025 (the “May 2025 Subscription Agreement”). The Notes and the $3.40 Warrants were issued and sold to the Selling Securityholders in a private placement that closed on October 28, 2025 (the “October 2025 Private Placement”), pursuant to a subscription agreement among us and such selling stockholders effective October 28, 2025 (the “October 2025 Subscription Agreement,” and together with the May 2025 Subscription Agreement, the “Subscription Agreements”). We are filing the registration statement of which this prospectus is a part pursuant to the Subscription Agreements on behalf of the Selling Securityholders.
We will not receive any proceeds from the sale of the Shares by the Selling Securityholders. We will, however, receive the net proceeds of any Warrants exercised for cash. Our registration of the Shares covered by this prospectus does not mean that the Selling Securityholders will offer or sell any of the Shares.
We will bear all costs, expenses and fees in connection with the registration of the Shares. The Selling Securityholders will bear all commissions and discounts, if any, attributable to their sales of the Shares. The Selling Securityholders and any of their permitted transferees may offer and sell the shares covered by this prospectus in a number of different ways and at varying prices. The Securities and Exchange Commission may take a position that each of the Selling Securityholders is an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended (the “Securities Act”). Additional information on the Selling Securityholders, and the times and manner in which they may offer and sell shares of our Common Stock under this prospectus, is provided under “Selling Securityholders” and “Plan of Distribution” in this prospectus.
Our Common Stock is traded on the Nasdaq Capital Market under the symbol “ARTL.” The last reported sales price of our shares of Common Stock on November 14, 2025 was $1.85 per share.
georgie18
6月前
ARTL...$1.69...🥳... Notice of Effectiveness hit right into today's news...This prospectus relates to the offer and resale, from time to time, by the selling securityholders named in this prospectus (the “Selling Securityholders”) of up to an aggregate of 899,972 shares of common stock, par value $0.001 per share (“Common Stock”), of Artelo Biosciences, Inc., consisting of (i) 215,292 shares of Common Stock issuable upon the conversion of convertible notes (the “Notes”), (ii) 246,498 shares of Common Stock issuable upon the exercise of warrants at an exercise price of $6.24 per share (the “$6.24 Warrants”), and (iii) 438,182 shares of Common Stock issuable upon the exercise of warrants at an exercise price of $3.40 per share (the “$3.40 Warrants”). The $6.24 Warrants and the $3.40 Warrants are collectively referred to herein as the “Warrants.” The shares of Common Stock issuable upon the conversion of the Notes and the Warrants are collectively referred to herein as the “Shares.”
The $6.24 Warrants were issued to the Selling Securityholders on October 28, 2025, upon the automatic conversion of a portion of the May 2025 Notes (as defined below) issued to the Selling Securityholders in a private placement that closed on May 1, 2025 (the “May 2025 Private Placement”), pursuant to a subscription agreement that we entered into with the Selling Securityholders, effective May 1, 2025 (the “May 2025 Subscription Agreement”). The Notes and the $3.40 Warrants were issued and sold to the Selling Securityholders in a private placement that closed on October 28, 2025 (the “October 2025 Private Placement”), pursuant to a subscription agreement among us and such selling stockholders effective October 28, 2025 (the “October 2025 Subscription Agreement,” and together with the May 2025 Subscription Agreement, the “Subscription Agreements”). We are filing the registration statement of which this prospectus is a part pursuant to the Subscription Agreements on behalf of the Selling Securityholders.
We will not receive any proceeds from the sale of the Shares by the Selling Securityholders. We will, however, receive the net proceeds of any Warrants exercised for cash. Our registration of the Shares covered by this prospectus does not mean that the Selling Securityholders will offer or sell any of the Shares.
We will bear all costs, expenses and fees in connection with the registration of the Shares. The Selling Securityholders will bear all commissions and discounts, if any, attributable to their sales of the Shares. The Selling Securityholders and any of their permitted transferees may offer and sell the shares covered by this prospectus in a number of different ways and at varying prices. The Securities and Exchange Commission may take a position that each of the Selling Securityholders is an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended (the “Securities Act”). Additional information on the Selling Securityholders, and the times and manner in which they may offer and sell shares of our Common Stock under this prospectus, is provided under “Selling Securityholders” and “Plan of Distribution” in this prospectus.
Our Common Stock is traded on the Nasdaq Capital Market under the symbol “ARTL.” The last reported sales price of our shares of Common Stock on November 14, 2025 was $1.85 per share.
georgie18
6月前
ARTL...$2.03...🥳...Hit $3.10 this morning...
georgie18
Member Level
Re: georgie18 post# 140
Tuesday, December 02, 2025 12:29:16 PM
Post#
145
of 149
ARTL...$1.93...🥳...Zero Borrow...Back in here on the $1.60 Range dip...
georgie18
Member Level
Re: georgie18 post# 698501
Monday, September 22, 2025 10:03:03 AM
Post#
699501
of 707708
ARTL...$6.02...Hod...🥳...$4.90s/$5.30s Looking better here...
georgie18
Member Level
Re: georgie18 post# 138
Monday, September 15, 2025 11:28:38 AM
Post#
139
of 139
ARTL...Added the $4.90 Dip...🥳
georgie18
Member Level
Re: None
Friday, September 12, 2025 8:45:53 PM
Post#
698332
of 698498
ARTL...$5.31...🥳... https://schrts.co/AUmYdsGy ...Oversold Chart with Open Gap in the $8 range...Dip caused by 3 million offering on Sept 5... Float under 3 Million...
SOLANA BEACH, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced that it has entered into a securities purchase agreement for an at-the market PIPE (private investment in public equity) for the purchase and sale of securities at a price of $10.45, consisting of: (a) 906,687 shares of common stock (or pre-funded warrants in lieu thereof); (b) three-year warrants to purchase 906,687 shares of common stock at an exercise price of $10.20 per share; and (c) three-year warrants to purchase 906,687 shares of common stock at an exercise price of $50.00 per share, for expected aggregate gross proceeds of approximately $9.475 million. This brings aggregate proceeds from private placements priced at-the-market since June 2025 to $10.9 million.
The Company intends to use the proceeds to launch its Solana (“SOL”)-centric digital asset treasury strategy, as well as to support Artelo’s ongoing business. Artelo’s treasury initiative marks a pivotal step in its long-term growth strategy, as it becomes the first publicly traded pharmaceutical company to adopt SOL—Solana’s native cryptocurrency—as a reserve asset. This move signals Artelo’s commitment to forward-thinking financial management and positions the Company at the intersection of biotechnology innovation and decentralized finance. By integrating SOL into its balance sheet, Artelo diversifies its treasury while gaining exposure to a next-generation monetary network that complements traditional cash management.
georgie18
6月前
ARTL...$1.93...🥳...Zero Borrow...Back in here on the $1.60 Range dip...
georgie18
Member Level
Re: georgie18 post# 698501
Monday, September 22, 2025 10:03:03 AM
Post#
699501
of 707708
ARTL...$6.02...Hod...🥳...$4.90s/$5.30s Looking better here...
georgie18
Member Level
Re: georgie18 post# 138
Monday, September 15, 2025 11:28:38 AM
Post#
139
of 139
ARTL...Added the $4.90 Dip...🥳
georgie18
Member Level
Re: None
Friday, September 12, 2025 8:45:53 PM
Post#
698332
of 698498
ARTL...$5.31...🥳... https://schrts.co/AUmYdsGy ...Oversold Chart with Open Gap in the $8 range...Dip caused by 3 million offering on Sept 5... Float under 3 Million...
SOLANA BEACH, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced that it has entered into a securities purchase agreement for an at-the market PIPE (private investment in public equity) for the purchase and sale of securities at a price of $10.45, consisting of: (a) 906,687 shares of common stock (or pre-funded warrants in lieu thereof); (b) three-year warrants to purchase 906,687 shares of common stock at an exercise price of $10.20 per share; and (c) three-year warrants to purchase 906,687 shares of common stock at an exercise price of $50.00 per share, for expected aggregate gross proceeds of approximately $9.475 million. This brings aggregate proceeds from private placements priced at-the-market since June 2025 to $10.9 million.
The Company intends to use the proceeds to launch its Solana (“SOL”)-centric digital asset treasury strategy, as well as to support Artelo’s ongoing business. Artelo’s treasury initiative marks a pivotal step in its long-term growth strategy, as it becomes the first publicly traded pharmaceutical company to adopt SOL—Solana’s native cryptocurrency—as a reserve asset. This move signals Artelo’s commitment to forward-thinking financial management and positions the Company at the intersection of biotechnology innovation and decentralized finance. By integrating SOL into its balance sheet, Artelo diversifies its treasury while gaining exposure to a next-generation monetary network that complements traditional cash management.
georgie18
8月前
ARTL...$6.02...Hod...🥳...$4.90s/$5.30s Looking better here...
georgie18
Member Level
Re: georgie18 post# 138
Monday, September 15, 2025 11:28:38 AM
Post#
139
of 139
ARTL...Added the $4.90 Dip...🥳
georgie18
Member Level
Re: None
Friday, September 12, 2025 8:45:53 PM
Post#
698332
of 698498
ARTL...$5.31...🥳... https://schrts.co/AUmYdsGy ...Oversold Chart with Open Gap in the $8 range...Dip caused by 3 million offering on Sept 5... Float under 3 Million...
SOLANA BEACH, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced that it has entered into a securities purchase agreement for an at-the market PIPE (private investment in public equity) for the purchase and sale of securities at a price of $10.45, consisting of: (a) 906,687 shares of common stock (or pre-funded warrants in lieu thereof); (b) three-year warrants to purchase 906,687 shares of common stock at an exercise price of $10.20 per share; and (c) three-year warrants to purchase 906,687 shares of common stock at an exercise price of $50.00 per share, for expected aggregate gross proceeds of approximately $9.475 million. This brings aggregate proceeds from private placements priced at-the-market since June 2025 to $10.9 million.
The Company intends to use the proceeds to launch its Solana (“SOL”)-centric digital asset treasury strategy, as well as to support Artelo’s ongoing business. Artelo’s treasury initiative marks a pivotal step in its long-term growth strategy, as it becomes the first publicly traded pharmaceutical company to adopt SOL—Solana’s native cryptocurrency—as a reserve asset. This move signals Artelo’s commitment to forward-thinking financial management and positions the Company at the intersection of biotechnology innovation and decentralized finance. By integrating SOL into its balance sheet, Artelo diversifies its treasury while gaining exposure to a next-generation monetary network that complements traditional cash management.
georgie18
9月前
ARTL...Added the $4.90 Dip...🥳
georgie18
Member Level
Re: None
Friday, September 12, 2025 8:45:53 PM
Post#
698332
of 698498
ARTL...$5.31...🥳... https://schrts.co/AUmYdsGy ...Oversold Chart with Open Gap in the $8 range...Dip caused by 3 million offering on Sept 5... Float under 3 Million...
SOLANA BEACH, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced that it has entered into a securities purchase agreement for an at-the market PIPE (private investment in public equity) for the purchase and sale of securities at a price of $10.45, consisting of: (a) 906,687 shares of common stock (or pre-funded warrants in lieu thereof); (b) three-year warrants to purchase 906,687 shares of common stock at an exercise price of $10.20 per share; and (c) three-year warrants to purchase 906,687 shares of common stock at an exercise price of $50.00 per share, for expected aggregate gross proceeds of approximately $9.475 million. This brings aggregate proceeds from private placements priced at-the-market since June 2025 to $10.9 million.
The Company intends to use the proceeds to launch its Solana (“SOL”)-centric digital asset treasury strategy, as well as to support Artelo’s ongoing business. Artelo’s treasury initiative marks a pivotal step in its long-term growth strategy, as it becomes the first publicly traded pharmaceutical company to adopt SOL—Solana’s native cryptocurrency—as a reserve asset. This move signals Artelo’s commitment to forward-thinking financial management and positions the Company at the intersection of biotechnology innovation and decentralized finance. By integrating SOL into its balance sheet, Artelo diversifies its treasury while gaining exposure to a next-generation monetary network that complements traditional cash management.
georgie18
9月前
ARTL...$5.31...🥳... https://schrts.co/AUmYdsGy ...Oversold Chart with Open Gap in the $8 range...Dip caused by 3 million offering on Sept 5... Float under 3 Million...
SOLANA BEACH, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced that it has entered into a securities purchase agreement for an at-the market PIPE (private investment in public equity) for the purchase and sale of securities at a price of $10.45, consisting of: (a) 906,687 shares of common stock (or pre-funded warrants in lieu thereof); (b) three-year warrants to purchase 906,687 shares of common stock at an exercise price of $10.20 per share; and (c) three-year warrants to purchase 906,687 shares of common stock at an exercise price of $50.00 per share, for expected aggregate gross proceeds of approximately $9.475 million. This brings aggregate proceeds from private placements priced at-the-market since June 2025 to $10.9 million.
The Company intends to use the proceeds to launch its Solana (“SOL”)-centric digital asset treasury strategy, as well as to support Artelo’s ongoing business. Artelo’s treasury initiative marks a pivotal step in its long-term growth strategy, as it becomes the first publicly traded pharmaceutical company to adopt SOL—Solana’s native cryptocurrency—as a reserve asset. This move signals Artelo’s commitment to forward-thinking financial management and positions the Company at the intersection of biotechnology innovation and decentralized finance. By integrating SOL into its balance sheet, Artelo diversifies its treasury while gaining exposure to a next-generation monetary network that complements traditional cash management.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
glenn1919
2週前
Hercules1
2月前
Zardiw
2月前
Stevenvegas
2月前
メールアドレスで登録
